The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer

• Главные авторы: Tingting Lu (Автор), Yufan Huang (Автор), Zhongjie Cai (Автор), Wangchun Lin (Автор), Xiaoxiao Chen (Автор), Ruijia Chen (Автор), Yingying Hu (Автор)
• Формат: ‌
• Опубликовано: Frontiers Media S.A., 2023-07-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Background: The EMPOWER-LUNG 3 clinical trial has shown that cemiplimab plus chemotherapy (CCT) significantly extended overall survival (OS) and progression-free survival (PFS) for patients with advanced non-small cell cancer (NSCLC) compared to placebo plus chemotherapy (PCT). However, the cost-eff...